NEU-411 is a brain-penetrant, potent and selective inhibitor of LRRK2 for the treatment of Parkinson’s disease (PD). Initial findings will be presented in a poster titled, “A Phase 1 Study of ...

A team of scientists has revealed a breakthrough discovery, linking genetic variants in the gene ITSN1 to a significantly ...

The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces the selection of five high priority targets through its Targets to Therapies Initiative — a program aimed at expanding the ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

The Aesthetic Society proudly announced the election of Tracy Pfeifer, MD, MS, as its new President during The Aesthetic MEET 2025, the premier event in aesthetic plastic surgery. A highly respected ...

The Aesthetic Foundation proudly announces the appointment of Patricia A. McGuire, MD, as its new President. Dr. McGuire, a board-certified plastic surgeon and esteemed breast surgery specialist, ...

Another potential catalyst for Arvinas is the upcoming presentation of Phase 1 healthy volunteer data for its LRRK2 degrader at the AD/PD meeting scheduled for April 1-4, 2025. This data could ...

BIIB122/DNL151 ( small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD) Denali and Biogen are jointly developing LRRK2 small molecule inhibitors. Biogen is leading the global ...

Innovation Center Ltd. has led to the discovery of new leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of cancer, leprosy, tuberculosis, colitis, ...

Denali has been working on small-molecule compounds capable of crossing the blood-brain barrier and Biogen has bought a licence to co-develop and co-market compounds known as LRRK2 inhibitors in ...